The Global Health Body Sounds Alert Over Severe Scarcity of Obesity Jabs

Less than 10% of patients eligible to benefit from weight-loss injections including Wegovy can access them, states the global health agency as it issues its initial advice on the medications.

With over a billion people worldwide currently living with obesity, it is calling for broader and more equitable availability to these injectable treatments.

According to forecasts, more than two billion will be obese by 2030 without intervention.

"Our latest guidelines affirms that excess weight is a chronic disease that can be addressed with holistic and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and distribution challenges are major obstacles to broad access to the jabs that can assist patients in reducing substantial body mass, notes the organization.

Skinny Jab Supply Crisis

Despite the current best projected outlook, the supply of GLP-1 therapies could only cover about 100 million people – under 10% of those who need them, as stated by the WHO.

The advice urges countries and companies to increase access, via strategies like voluntary licensing.

Exclusive production rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.

The Way Weight-Loss Jabs Function

These medications imitate a biological compound to slow digestion, curb appetite and enhance satiety so people reduce food intake.

Individuals usually start to lose weight within a few weeks of beginning the regular doses.

Research points to people may put most of the weight back on after a year of discontinuing the drug, because their typical food cravings return.

Being carrying excess weight raises your chance for developing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.

Obesity affects people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.